Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 13.6d

Immunosuppression Use for Maintenance by Regimen

Prior to Discharge, 2000 to 2009

Recipients with Heart-Lung Transplants

  Transplant Year
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Functioning Graft at Discharge 33 21 22 17 35 29 24 29 21 24
With Immunosuppression Info 33 21 22 17 35 29 24 28 20 24
Tac 0.0% 0.0% 0.0% 5.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Steroids 0.0% 4.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + Steroids 3.0% 0.0% 0.0% 0.0% 2.9% 0.0% 4.2% 0.0% 0.0% 0.0%
Tac + Steroids 3.0% 0.0% 4.5% 11.8% 11.4% 3.4% 4.2% 14.3% 5.0% 8.3%
CyA + MMF/MPA + Steroids 36.4% 33.3% 22.7% 17.6% 17.1% 10.3% 8.3% 3.6% 5.0% 8.3%
Tac + MMF/MPA + Steroids 9.1% 19.0% 18.2% 5.9% 34.3% 41.4% 62.5% 67.9% 85.0% 62.5%
CyA + OtherAntimet + Steroids 33.3% 38.1% 27.3% 23.5% 14.3% 34.5% 12.5% 0.0% 5.0% 0.0%
Tac + OtherAntimet + Steroids 6.1% 4.8% 18.2% 29.4% 14.3% 6.9% 4.2% 10.7% 0.0% 12.5%
Tac + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.0% 2.9% 0.0% 0.0% 0.0% 0.0% 0.0%
Other Regimen 9.1% 0.0% 9.1% 5.9% 2.9% 3.4% 4.2% 3.6% 0.0% 8.3%


Source: OPTN/SRTR Data as of October 1, 2010.

Percentages in each column sum to 100 percent.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.